arrow
K

Kim De Veirman

translational oncology research center
H指数:31
被引数:2,944

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape

B7-H3纳米抗体为基础的CAR T细胞可控制多发性骨髓瘤的生长,而双重BCMA/B7-H3 CAR T细胞可克服抗原逃逸。

2025-11-170
OAAI
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy

免疫组学鉴定了含α-半乳糖基神经酰胺的信使RNA-脂质纳米颗粒疫苗在多发性骨髓瘤治疗中的抗原。

2025-04-290
OA
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse

从头DNA甲基转移酶3B是MYC在多发性骨髓瘤中的新型表观遗传调控因子,代表了一个有前景的治疗靶点以对抗复发。

2025-04-171
OA
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (vol 17, 128, 2024)

硼替佐米释放的硅酸-胶原蛋白干凝胶用于多发性骨髓瘤的溶骨性骨病和微小残留病灶的局部治疗(卷17,128,2024)

2025-01-240
OA
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

释放硼替佐米的二氧化硅-胶原干燥凝胶用于局部治疗多发性骨髓瘤的溶骨性骨和最小残留疾病

2024-12-180
OAAI
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization

细胞外结构域对嵌合抗原受体激活的审查: 针对多发性骨髓瘤细胞的单结构域抗体的经验突出了逐案优化的必要性

2024-04-190
OAAI
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia

AXL特异性单域抗体在急性髓系白血病中的诊断潜力和抗肿瘤活性

2024-01-011
OAAI